# OnCo record rinuagene-biotechnology (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/rinuagene-biotechnology/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "rinuagene-biotechnology" ;
  schema:name "RinuaGene Biotechnology"@en ;
  schema:alternateName "RinuaGene"@en ;
  schema:description "RinuaGene develops mRNA medicines. Its lead product, RG002, is a therapeutic vaccine meant to make the immune system clear cervical precancer caused by HPV types 16 and 18, before it can turn into cancer."@en ;
  schema:url <https://onco.cc/companies/rinuagene-biotechnology/>, <https://www.rinuagene.com/> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://www.rinuagene.com/>, <https://www.rinuagene.com/pipeline/>, <https://clinicaltrials.gov/study/NCT06273553> ;
  schema:addressCountry "CN" ;
  onco:cancers <https://onco.cc/cancers/cervical/> ;
  onco:sections <https://onco.cc/fronts/immunotherapy/>, <https://onco.cc/fronts/prevention/> ;
  onco:technologies <https://onco.cc/technologies/interception-vaccination/> .